BMS aims to improve on existing Interferon-based standard of carein
conjunction with Peg Interferon and Ribavirin, and Interferon and/ or
Ribavirin to minimize resistance of hepatitis C virus
![](/IMG/741/45741/hepbviruscopy.jpg)
According to statistics, more
than two billion people show evidence of hepatitis B virus (HBV)
infection. About 350 million people have chronic HBV. Globally, 170
million people have chronic HCV infection and 20-30 percent of
chronically infected will develop cirrhosis, one-third of which will
progress to hepatocellular carcinoma (HCC). Hepatitis C virus (HCV) is
the leading indication for liver transplantation in many parts of the
world.
Identifying the need to curb hepatitis, Bristol-Myers Squibb (BMS), the
global biopharma company, has intensified its activities to find remedy
for HBV and HCV, and restrict the spread of HCC.
“Asia Pacific region is becoming the hotbed for HBV and HCV and that
in-turn reflects an increase in the liver cancer cases. There is an
urgent need to manage and restrict liver cancer by following an
integrated approach,” says Mr Andreas Pangerl, global medical lead –
hepatitis, Bristol-Myers Squibb.
Hepatitis B
Untreated hepatitis B is responsible for one million deaths worldwide
each year. Giving insights on the initiatives taken by BMS to restrict
HBV, Mr Paul Slade, executive director – virology, Bristol-Myers
Squibb, says, “Hundreds of millions of people in the Asia Pacific
region are at risk of developing severe liver disease, it is high time
to find a promising remedy for this. The main challenge in tackling
chronic hepatitis B is to find a complete cure. BMS’ Baraclude is a
leading treatment regimen for chronic hepatitis B patients. Over
430,000 patients were treated in the past five years worldwide.”
Baraclude (entecavir) was discovered by BMS as part of a large
screening program to identify antiviral treatments. Baraclude was
originally being investigated as a potential compound to treat the
herpes viruses. It soon emerged that Baraclude had properties that made
it a valuable drug candidate to treat the hepatitis B virus,
demonstrating potent antiviral activity and high selectivity.
Bristol-Myers Squibb embarked on more than eight years of clinical
research, which ultimately demonstrated that Baraclude has been
identified as a potent, oral antiviral therapy that can effectively
reduce viral load to undetectable levels (<300 copies/mL) in the
majority of patients chronically infected with hepatitis B.
Baraclude has been approved for adults with chronic hepatitis B in
several Asia Pacific countries including China and India (2005); Japan,
Korea and Taiwan (2006); and Hong Kong (2007).
Hepatitis C
“The combination of PEG Interferon and Ribavirin is the current
treatment option for HCV. About 50-80 percent of patients can be cured
depending on the viral genotype, but there are associated adverse
events including depression, fatigue, flu-like symptoms, and anemia.
Duration of therapy for most HCV genotypes is 48-week with PEG
Interferon and Ribavirin. The HCV strategy at BMS is three-pronged with
the aim of improving treatment options across all genotypes, enhancing
Interferon therapy (IFN-alpha) +/- small molecule antivirals,
developing combinations of oral antivirals, +/– IFN and/or Ribavirin.
Another compound, Brivanib is under broad-spectrum phase III
development plan for Brivanibin unresectable HCC,” adds Mr Slade.
"In India, more than 30 million people are
infected with HBV and 19
million with HCV. In 2011, the government of India has made HBV a
priority disease area. All children born in India will now receive HBV
vaccine"
— Ms Phangisile Mtshali Manciya, director – Delivering Hope,
Bristol-Myers Squibb Foundation
The phase II study of BMS investigational compound for HCV — Pegylated
Interferon Lambda (PegIFN Lambda) — showed safety, viral response, and
impact of host genotype. Based on current data, PegIFN Lambda shows
promise across a broad range of doses and viral genotypes. Study is
ongoing; and the results are expected by the end of 2011. BMS’ HCV DAAs
NS5A Replication Complex Inhibitor (BMS-790052) and NS3 Protease
Inhibitor (BMS-650032) are in phase II. BMS aims to improve on existing
Interferon-based standard of care in conjunction with Peg Interferon
and Ribavirin, and Interferon and or Ribavirin to minimize resistance
of HCV. Broad-spectrum phase III development plan of BMS is ongoing for
another inhibitor — Brivanib — in HCC. Brivanib Biomarker Program is
exploring potential biomarkers that may predict efficacy and safety.
Delivering hope
Delivering Hope is an initiative of BMS Foundation, an independent
philanthropic wing of BMS, to prevent hepatitis in Asia. The foundation
is taking several initiatives in China and India. Ms Phangisile Mtshali
Manciya, director – Delivering Hope, Bristol-Myers Squibb Foundation,
said, “The foundation targets funding and takes initiatives to improve
health outcomes at the community level; takes care of community
mobilization and supportive services; and provides trainings to
healthcare workers. The Foundation has awarded four new grants in China
and India totaling nearly $1 million.”
"Asia Pacific region is becoming the hotbed
for HBV and HCV. There is an urgent need to manage and restrict liver
cancer by following an integrated approach"
— Mr Andreas Pangerl, global medical lead – hepatitis,
Bristol-Myers Squibb
Commenting on the initiatives taken in China
and India, Ms Manciya, says, “In China, approximately 40 million people
are infected with HCV. Testing for hepatitis is not accessible to more
than 50 percent of the population. The Chinese government has declared
HCV an urgent public health issue and named it as one of China’s top
five deadly epidemics. Delivering Hope has made great strides in China
since 2002, by policy outreach and contributing to the development of
HCV operational research across the country.”
“In India, more than 30 million people are infected with HBV and 19
million with HCV. In 2011, the government of India has made HBV a
priority disease area. All children born in India will now receive HBV
vaccine. The initiatives taken by Delivering Hope in India include the
Hepatitis Foundation of Tripura (HFT) Vaccination Program; the Health
Oriented Programs Education (HOPE) initiative for generating awareness
of HBV in school children; development of a curriculum that can be
adapted by local teachers across the school system in Uttar Pradesh;
and to address the high hepatitis infection rates in the area, the
United Way of Mumbai, together with Delivering Hope have developed a
comprehensive targeted hepatitis education program,” she concludes.
With Asia Pacific region gaining prominence because of the high
prevalence of hepatic disease, BMS’ positive trial outcomes and other
preventional initiatives raise confidence.
Pradeep Kumar in Bangkok
The author was in Bangkok at the invitation of Bristol-Myers Squibb